Phaseline

Targets › BUTYRATE

BUTYRATE: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Immunology; next expected readout Jun 2029.

Open in Phaseline: the race on BUTYRATE, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of NebraskaSunButyrate-TG
Short-chain fatty acid (SCFA) supplement; promotes gut health and microbiome function
BUTYRATEPhase 1Congenital Heart Disease (CHD)Jun 2029

Conditions

Congenital Heart Disease (CHD) (1)

Modalities

small molecule (1)

Companies

University of Nebraska (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.